What next? Sustaining anti-obesity pharmacotherapy success through metabolic maintenance
- 15 August 2026
- journal article
- perspective
- Published by Springer Nature in International Journal of Obesity
- p. 1-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026Diabetes Care, 2025
- American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 UpdateEndocrine Practice, 2025
- A Systematic Review of “Food Is Medicine” Randomized Controlled Trials for Noncommunicable Disease in the United States: A Scientific Statement From the American Heart AssociationCirculation, 2025
- Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyObesity, 2025
- Estimated Impact Of Medically Tailored Meals On Health Care Use And Expenditures In 50 US StatesHealth Affairs, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Medical Nutrition Therapy Interventions Provided by Dietitians for Adult Overweight and Obesity Management: An Academy of Nutrition and Dietetics Evidence-Based Practice GuidelineJournal of the Academy of Nutrition and Dietetics, 2022
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionDiabetes, Obesity and Metabolism, 2022
- Effects of Diet versus Gastric Bypass on Metabolic Function in DiabetesNew England Journal of Medicine, 2020